<DOC>
	<DOCNO>NCT00461149</DOCNO>
	<brief_summary>Epidemiological data indicate patient active acromegaly reduce life expectancy cardiovascular ( 60 % ) respiratory disease ( 25 % ) mainly ( 1-10 ) . A post-treatment GH value &lt; 5 mU/liter ( equal &lt; 2.5 μg/liter ) IGF-I normal range age recognize predictive survival index . Since introduction clinical use approximately two decade ago , somatostatin analog consider cornerstone medical therapy acromegaly . After 12 month treatment octreotide-LAR , control GH IGF-I excess , achieve 54 % 63 % unselected patient ( 11 ) . The proportion subject achieve IGF-I normalization increase significantly time ( 12 ) . Significant tumor shrinkage also report number study ( 13,14 ) : average 50 % tumor decrease achieve drug use exclusively , surgery radiotherapy ( 14 ) . In 99 unselected newly diagnose patient 12 month treatment somatostatin analogue report control GH level 57.6 % IGF-I level 45.5 % great 50 % tumor shrinkage 44.4 % ( 15 ) . The dose LAR different study range 10-40 mg every 28 day ( q28d ) : high dos generally administer patient control GH IGF-I excess low dos . As report meta-analysis ( 11 ) rate IGF-I normalization tend low octreotide-LAR dose raise : 90 % patient treat 10 mg , 61 % 20 mg 53 % 30 mg . However , benefit increase dose octreotide-LAR report study ( 16-18 ) . Data dose escalation octreotide-LAR give first-line therapy newly diagnose patient acromegaly lacking .</brief_summary>
	<brief_title>Dose Escalation Octreotide-LAR First-Line Therapy Resistant Acromegaly</brief_title>
	<detailed_description>This analytical , interventional , 24-month , open , prospective study investigate effect progressive increase octreotide-LAR dos newly diagnose patient acromegaly . Primary outcome measure GH IGF-I control tumor shrinkage ; secondary outcome measure glucose tolerance . At diagnosis every six month , 24-48 hour change treatment dos apply , measure : 1 . Serum IGF-I level twice single sample time 0 GH profile ; GH level calculate mean value 3-6 sample draw every 30 min ; average value consider statistical analysis ; 2 . Tumor volume MRI study perform clinical 1T 1.5T scanner , use T1 weight gradient recalled-echo sagittal coronal plane , already report ( 15,21,22 ) . The acquisition repeat administration 0.1 mmoles gadolinium chelate ( diethylene-triamine pentacetate ) . In patient MRI perform diagnosis 6 , 12 , 24 month treatment . The maximal sagittal , axial coronal diameter measure , tumor volume calculate De Chiro Nelson formula [ ( volume= sagittal*coronal*axial diameter ) *π/6 ] . According previous study ( 13,21 ) post-treatment MRI , tumor shrinkage assess percent decrease tumor volume compare baseline . 3 . Glucose tolerance assay glucose insulin level fast . Only diagnosis glucose insulin also measure every 30 minute 2 hour oral administration 75 g glucose dilute 250 ml saline solution . In four patient glucose load perform overt diabetes ( fast glucose 7 mmol/L two consecutive measurement ) ( 25 ) . Diabetes mellitus diagnose another eight patient 2 hour oGTT glucose &gt; 11 mmol/L ( 25 ) . Impaired glucose tolerance ( IGT ) glucose level &gt; 7.8 mmol/L &lt; 11 mmol/L 2 hour oGTT and/or impaired fast glucose ( IFG ) glucose level 5.6 6.9 mmol/L fasting diagnose 20 patient ( 25 ) . Glucose tolerance normal ( 5.6 mmol/L fast ) 24 patient . To predict insulin resistance [ HOMA-R ( % ) ] ß-cell function [ HOMA-β ( % ) ] use HOMA ( homeostatic model assessment ) accord Matthews et al . ( 24 ) . By assume normal-weight healthy subject age &lt; 35 year HOMA-β 100 % HOMA-R 1 , value individual patient assessed insulin glucose concentration formula : HOMA-R = [ insulin ( mU/L ) *fasting glucose ( mmol/L ) ] / 22.5 ; HOMA-β ( % ) = [ 20*insulin ( mU/L ) ] / [ glucose ( mmol/L ) -3.5 ] . Treatment protocol Before start therapy , patient receive acute test s.c. octreotide dose 0.1 mg morning overnight fast least 2 hrs bedrest , investigate patient ’ tolerability somatostatin analogue ( 25 ) . Then , patient treat octreotide-LAR i.m . initial dose 20 mg every 28 day three month . Subsequently , LAR treatment maintain dose patient achieve GH level ≤2.5 μg/liter IGF-I level normal range ( Group A ) , increase 30 mg every 28 day patient GH level &gt; 2.5 μg/liter and/or IGF-I level normal range . After another 9 month treatment 30 mg/q28d , dose maintain 15 patient achieve GH level ≤2.5 μg/liter IGF-I level normal range ( Group B ) increase 40 mg/q28 day fast GH level still &gt; 2.5 μg/liter and/or IGF-I level normal range ( Group C ) .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>patient newly diagnose acromegaly age 18 year previous treatment acromegaly primary surgery concomitant hyperprolactinemia require combine treatment dopamineagonist primary treatment lanreotide treatment duration le 24 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>GH</keyword>
	<keyword>IGF-I</keyword>
	<keyword>Pituitary tumor</keyword>
	<keyword>Octreotide</keyword>
</DOC>